The observation that rosiglitazone and 5-ASA activate PPAR-γ signaling in different cell types to ameliorate DSS-induced colitis might explain why, paradoxically, a combination of two PPAR-γ agonists has therapeutic effects that are superior to those of treatment with just one agonist. Here, PPARG is linked to colitis.